Correspondence to: Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients

AllergyVolume 77, Issue 3 p. 1073-1074 CORRESPONDENCE Correspondence to: Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients Eamonn Maher, Corresponding Author Eamonn Maher eamonn.maher@nyulangone.org Department of Dermatology, NYU Langone, New York City, New York, USA Correspondence Eamonn Maher, NYU Department of Dermatology, New York City, New York, USA. Email: eamonn.maher@nyulangone.orgSearch for more papers by this authorFrank Martiniuk, Frank Martiniuk JME Group, Inc and Psychogenics Center, Parasmus, New Jersey, USASearch for more papers by this authorWilliam Levis, William Levis Department of Dermatology, Bellevue Hospital, New York City, New York, USASearch for more papers by this author Eamonn Maher, Corresponding Author Eamonn Maher eamonn.maher@nyulangone.org Department of Dermatology, NYU Langone, New York City, New York, USA Correspondence Eamonn Maher, NYU Department of Dermatology, New York City, New York, USA. Email: eamonn.maher@nyulangone.orgSearch for more papers by this authorFrank Martiniuk, Frank Martiniuk JME Group, Inc and Psychogenics Center, Parasmus, New Jersey, USASearch for more papers by this authorWilliam Levis, William Levis Department of Dermatology, Bellevue Hospital, New York City, New York, USASearch for more papers by this author First published: 25 February 2022 https://doi.org/10.1111/all.15185 Funding information: No external funding for this manuscript. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume77, Issue3March 2022Pages 1073-1074 RelatedInformation